Cord blood stem cells plus azacitidine for advanced blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced bone marrow blood cancer: MDS (intermediate to very high risk), CMML-2, or AML (with specific prior cancer history or bone marrow findings).
- Your doctors decide you are not eligible for a stem cell transplant from a matched donor (allogeneic HSCT).
- You are being considered for azacitidine (azacitidine) by your local care team for your diagnosis.
- You are 18 to 80 years old, and you can sign (or your legal representative can sign) the consent form.
- Your organ and heart function meet safety thresholds: liver/bilirubin and kidney tests are limited, and heart pump strength is adequate (LVEF 50% or higher).
- You have enough ability to carry out daily activities (ECOG 0 to 2) and your kidney filtering rate is at least 30.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.